Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study

L. E. Hendriks*, J. L. Derks, P. E. Postmus, R. A. Damhuis, R. M. A. Houben, E. G. C. Troost, M. M. Hochstenbag, E. F. Smit, A. -M. C. Dingemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Web of Science)
40 Downloads (Pure)


Purpose: To analyse the prognostic impact on overall survival (OS) of single versus multiple organ metastases, organ affected, and local disease status in a population based stage IV non-small cell lung cancer (NSCLC) cohort. Methods: In this observational study, data were analysed of all histologically confirmed stage IV NSCLC patients diagnosed between 1 January 2006 and 31 December 2012 registered in the Netherlands Cancer Registry. Location of metastases before treatment was registered. Multivariable survival analyses [age, gender, histology, M-status, local disease status, number of involved organs, actual organ affected] were performed for all patients and for an (18)fluorodeoxyglucose-positron emission tomography ((18)FDG-PET)-staged subgroup. Results: 11,094 patients were selected: 60% male, mean age 65 years, 73% adenocarcinoma. Median OS for 1 (N = 5676), 2 (N = 3280), and >= 3 (N = 2138) metastatically affected organs was 6.7, 4.3, 2.8 months, respectively (p <0.001). Hazard ratio (HR) for 2 versus 1 organ(s) was 1.33 (p <0.001), for >= 3 versus 1 organ(s) 1.91 (p <0.001). Results were confirmed in the (18)FDG-PET-staged cohort (N = 1517): patients with single organ versus 2 and >= 3 organ metastases had higher OS (8.6, 5.7, 3.8 months, HR 1.40 and 2.17, respectively, p <0.001). In single organ metastases, OS for low versus high TN-status was 8.5 versus 6.5 months [HR 1.40 (p <0.001)]. (18)FDG-PET-staged single organ metastases patients with low TN-status had a superior OS than those with high TN-status (11.6 versus 8.2 months, HR 1.62, p <0.001). Conclusion: Patients with single organ metastases stage IV NSCLC have a favourable prognosis, especially in combination with low TN status. They have to be regarded as a separate subgroup of stage IV disease.
Original languageEnglish
Pages (from-to)2534-2544
JournalEuropean Journal of Cancer
Issue number17
Publication statusPublished - Nov 2015


  • Non-small cell lung cancer
  • Stage IV
  • Prognosis
  • Metastases
  • Local disease status

Cite this